Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruck, Tobias, Bittner, Stefan, Wiendl, Heinz, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519957/
https://www.ncbi.nlm.nih.gov/pubmed/26204829
http://dx.doi.org/10.3390/ijms160716414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519957/
https://www.ncbi.nlm.nih.gov/pubmed/26204829
http://dx.doi.org/10.3390/ijms160716414

Ejemplares similares